US secures $1bn of GSK-Vir Covid-19 treatment – report

by | Nov 17, 2021

The United States has signed about $1bn of contracts to buy the antibody-based Covid-19 treatment developed by GlaxoSmithKline and Vir Technology of the US, according to a report.
GSK said the deal meant the number of doses of sotrovimab secured for treatment was more than 750,000 globally with supply expected to start on 17 December. The US will have an option to buy extra doses until the end of March 2022, Reuters reported.

Sotrovimab is authorised for emergency use in the US to prevent mild or moderate cases of the virus from getting worse. The companies did not say how many doses the US had secured after Canada bought 10,000 treatments and the EU secured up to 220,000.

The treatment cuts the risk of hospitalisation or death by 79% in adults with mild-to-moderate Covid-19.

“Given ongoing evidence, which demonstrates its ability to maintain activity against the tested circulating variants of concern, including Delta, we are confident sotrovimab will continue to be important,” Vir’s chief executive George Scangos said in a statement.

Related articles

Ryanair passenger numbers jump 9% in December

Ryanair passenger numbers jump 9% in December

(Sharecast News) - Budget airline Ryanair reported a 9% jump in December passenger numbers on Wednesday. Traffic rose to 12.54 million from 11.52m in the same month a year earlier, while the load factor - which gauges how full the planes are - ticked down to 91% from...

Wizz Are passenger numbers soar in December

Wizz Are passenger numbers soar in December

(Sharecast News) - Hungary-based budget airline Wizz Air reported a strong rise in December passenger numbers as demand continued to rebound from the Covid pandemic. The company on Wednesday said it carried 4,964,857 passengers, an 18.8% increase year on year. For the...

Trending stories

Join our mailing list

Subscribe to our mailing list to receive regular updates!

x